STD Basic Package (DO NOT USE)

We are required to report positive results for this test to the CDC.


Fasting Required: No

Specimen: Blood

Results: 3-5 Business Days
Note: Result turn around times are an estimate and are not guaranteed. Our reference lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.

Tests Included:

HSV II: There is a considerable homology between HSV I and HSV II antigens, so that antibodies formed against either virus are highly cross-reactive. This assay is based on purified recombinant G-2 antigen and is specific for type II antibodies. Moreover, this assay is highly sensitive and specific and will not detect antibodies to HSV I.

HIV: Human immunodeficiency virus (HIV 1/O/2), the etiologic agent of the acquired immunodeficiency syndrome (AIDS) is a cytopathic retrovirus. This test uses recombinant antigen sources and detects antibodies by specific immune binding and subsequent chemiluminescent reaction (ICMA technology). Sensitivity and specificity of this assay are 100% and 99.9% respectively. Sera which are repeatedly reactive in two out of three tests are subject to confirmatory HIV-1 testing by the Western blot method. Some individuals may be initially reactive by the preliminary test and negative or indeterminate by Western blot. This may be caused by other viral antibodies or autoantibodies which cross react with the viral antigens although this is rare.

Hepatitis C: Following the development of sensitive and specific testing for hepatitis B, 90% of post-transfusion hepatitis is now hepatitis C. A gene product (c100) of hepatitis C virus (HCV) was isolated and an assay for anti-HCV developed. The assay detects antibody to a presumptive togavirus or flavivirus which may be an etiologic agent of non-A, non-B hepatitis (which may not be a unitary disease entity).
For blood donors, hepatitis C serology correlates with surrogate tests for non-A, non-B hepatitis (ALT and anti-HBc). Since hepatitis C serology identifies a broader group of infected individuals than surrogate testing, it reduces risk of HCV during transfusion. Studies in hemophiliacs indicate that antibody to HCV is a reliable marker of HCV.